Abingworth
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Development Stage, Clinical Co-Development
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, China, France, Italy, Denmark, Switzerland, Spain, South Korea, Ireland, Netherlands, New Zealand, Sweden, Belgium, Norway, Finland
Industries Focus
- Life Sciences
- Healthcare Services
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Healthcare Technology
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Infectious Diseases
- Immunology
- Genomics
Investment Size:
5,000,000 to 50,000,000 USD
Investor Details Founded: 1973
Abingworth is a transatlantic life sciences investment firm founded in 1973, dedicated exclusively to the life sciences and healthcare sectors. With over $2 billion in assets under management, the firm invests across all stages of company development, including early and late-stage venture financing, growth equity, and public companies. Abingworth has invested in over 185 life science companies, leading to more than 75 IPOs and 50+ mergers and acquisitions. The firm operates offices in London, Menlo Park (California), and Boston, providing a global presence to support its portfolio companies.
Abingworth's investment strategy focuses on therapeutic areas such as biotechnology, pharmaceuticals, medical devices, healthcare services, diagnostics, digital health, and life sciences. The firm has a strong track record in supporting companies through various stages of development, from seed and early-stage investments to clinical co-development. Abingworth's team of experienced professionals offers expertise in scientific and business domains, as well as investment banking, recruitment, and legal knowledge, to assist portfolio companies in achieving their growth objectives.
In August 2022, Abingworth was acquired by The Carlyle Group, a global investment firm, to bolster Carlyle's healthcare franchise. This acquisition has further enhanced Abingworth's capabilities in the life sciences sector, enabling the firm to continue its mission of transforming cutting-edge science into novel medicines by providing capital and expertise to top-caliber management teams building world-class companies.
Requirements
- Strong scientific and clinical data
- Experienced management teams
- Innovative therapeutic approaches
- Potential for significant market impact
- Alignment with Abingworth's investment strategy
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Nouscom
- Avillion
- Sanofi Ventures
- Jasper Therapeutics
- AdvanCell
- Solve Therapeutics
Mentioned In
-
$99.00
-
$24.95
-
$24.95
-
$19.95
-
$49.95
-
$19.95
-
$39.95
-
$99.00
-
$245.00
Claim this Investor
Are you an official representative of Abingworth?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim